Minapharm Secures Investment from Admaius Capital Partners to Fuel Biotech Expansion in Africa and Beyond
Is access to cutting-edge biotechnology limited by geography and cost? A recent landmark investment signals a shift, promising to broaden the reach of innovative therapies across the Middle East and Africa. Minapharm, a leading Egyptian biopharmaceutical company, has partnered with Admaius Capital Partners, a private equity firm focused on the African market, to accelerate its regional and global expansion. This collaboration isn’t just about financial gain; itS about building self-sufficiency in pharmaceutical manufacturing and delivering affordable,life-saving treatments to underserved populations.
A Strategic Partnership Forging a New Path in Biopharmaceuticals
Triquera B.V., the majority shareholder of Minapharm, announced the minority investment from Admaius Capital Partners on July 28, 2025. This deal represents a notable vote of confidence in Minapharm’s capabilities and its potential to become a major player in the global biotechnology landscape.
Minapharm distinguishes itself through its comprehensive, end-to-end manufacturing capabilities. Operating state-of-the-art facilities in both Cairo, Egypt, and Berlin, Germany, the company specializes in the complex production of:
Recombinant Proteins: Crucial components in many modern therapies, including insulin and growth hormones.
Viral Vectors: Essential for gene therapy, delivering genetic material to target cells. Advanced Biologics: A broad category encompassing therapies derived from living organisms, offering highly targeted treatments.
This integrated approach, from drug substance to finished product, positions Minapharm uniquely within the Middle East and Africa, a region often reliant on imports for these critical medicines. World Health Organization – Access to Medicines highlights the critical need for increased local pharmaceutical production in developing nations.
Expanding Access to Innovative Therapies
The partnership with Admaius is strategically focused on several key areas:
Increased Regional Availability: The primary goal is to make genetically engineered therapies more accessible and affordable in Africa and the Middle East. This addresses a significant healthcare disparity, where access to advanced treatments is often limited by cost and logistical challenges.
Technology Licensing & expansion: Minapharm holds proprietary technologies in vital areas like monoclonal antibodies (used in cancer treatment and autoimmune diseases), cell and gene therapies (offering potential cures for genetic disorders), and vaccines. The investment will fuel the expansion of licensing these technologies, potentially impacting global health outcomes. Many of Minapharm’s technologies have already been incorporated into products approved by the stringent regulatory standards of the U.S. Food and Drug Management (FDA). U.S. Food and Drug Administration
Strategic Acquisitions (cdmos): A key component of the growth strategy involves exploring acquisitions of Contract Progress and Manufacturing Organizations (CDMOs) globally. This will bolster Minapharm’s manufacturing capacity, expand its technological expertise, and strengthen its position as a competitive force in the international biotech market. Contract Development and Manufacturing Organizations (CDMOs) – Informa Pharma Intelligence provides detailed insights into the CDMO landscape.
Leadership Perspectives: A Shared Vision for the Future
The enthusiasm surrounding this partnership is evident in statements from key leaders:
“With Admaius, we gain not only capital but a strategic partner whose insight, alignment, and ambition match our own. Together, we are advancing regional self-sufficiency and expanding the global reach of our innovations,” stated Dr.Wafik Bardissi, Chairman and CEO of Minapharm.
Marlon Chigwende, Managing Partner of Admaius Capital Partners, described the deal as a “landmark transaction,” emphasizing the unique value of the asset built by the founding families: “They have built a unique asset on the African and European continents that combines scale, growth, and impact to fight cancer and other awful diseases.”
Ahmed Rady,Managing Director at admaius,highlighted Minapharm’s strengths: “This partnership is about scaling a homegrown champion that combines cutting-edge global know-how with end-to-end manufacturing excellence.”
Dr.Shaheer Bardissi, Co-CEO of Minapharm, underscored the broader impact: ”This strategic collaboration with Admaius will accelerate and scale Minapharm’s vision of translating cutting-edge scientific innovation into affordable therapies, while advancing global scientific frontiers in immunotherapy and advanced therapy medicinal products.”
Deal Advisory Details
The prosperous completion of this investment was facilitated by expert advisory teams:
* Triquera & Existing Shareholders: Zilla Capital served
